{"id":7869,"date":"2021-06-23T16:23:51","date_gmt":"2021-06-23T14:23:51","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=7869"},"modified":"2021-06-24T10:03:43","modified_gmt":"2021-06-24T08:03:43","slug":"poxel-announces-the-approval-of-twymeeg","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/","title":{"rendered":"Poxel announces the approval of Twymeeg"},"content":{"rendered":"

TWYMEEG\u00ae<\/sup> is a first-in-class drug with a unique dual mechanism of action for the treatment of Type 2 Diabetes across the continuum of the current treatment paradigm, both as a monotherapy or as an add-on to other glucose lowering therapies.<\/b><\/p>\n

The approval in Japan triggers a JPY 1.75 billion (approximately EUR 13.3 million, USD 15.9 million) milestone payment to Poxel from Sumitomo Dainippon Pharma.<\/b><\/p>\n

TWYMEEG\u2019s target product launch is anticipated in fiscal year 2021.<\/b><\/p>\n

The Japanese approval for TWYMEEG is supported by positive results from the Phase 3 TIMES program in over 1,100 patients in Japan.<\/b><\/p>\n

 <\/p>\n

Poxel has been supported for several years by Andera Life Sciences, Andera Partners’ team dedicated to therapeutic innovation. For Rapha\u00ebl Wisniewski, partner in the Life Sciences team :”the approval of a product is a real achievement in the life of the companies we support. We are convinced of the potential of TWYMEED and the interest it represents for patients with type II diabetes<\/em>.”<\/p>\n

The approval of TWYMEEG\u00ae is the second drug approval since the beginning of 2021 for the Andera Life Sciences portfolio. Last March, Ontozri\u00ae (cenobamate), developed by Arvelle Therapeutics, was approved by the European Commission for the treatment of drug-resistant focal seizures in adults.<\/p>\n

Click here<\/a> to read the press release.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

TWYMEEG\u00ae is a first-in-class drug with a unique dual mechanism of action for the treatment of Type 2 Diabetes across the continuum of the current treatment paradigm, both as a monotherapy or as an add-on to other glucose lowering therapies. The approval in Japan triggers a JPY 1.75 billion (approximately EUR 13.3 million, USD 15.9…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-7869","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"\nPoxel announces the approval of Twymeeg - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Poxel announces the approval of Twymeeg - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"TWYMEEG\u00ae is a first-in-class drug with a unique dual mechanism of action for the treatment of Type 2 Diabetes across the continuum of the current treatment paradigm, both as a monotherapy or as an add-on to other glucose lowering therapies. The approval in Japan triggers a JPY 1.75 billion (approximately EUR 13.3 million, USD 15.9...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-23T14:23:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-06-24T08:03:43+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Poxel announces the approval of Twymeeg\",\"datePublished\":\"2021-06-23T14:23:51+00:00\",\"dateModified\":\"2021-06-24T08:03:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/\"},\"wordCount\":211,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/\",\"name\":\"Poxel announces the approval of Twymeeg - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2021-06-23T14:23:51+00:00\",\"dateModified\":\"2021-06-24T08:03:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Poxel announces the approval of Twymeeg\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Poxel announces the approval of Twymeeg - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/","og_locale":"en_US","og_type":"article","og_title":"Poxel announces the approval of Twymeeg - ANDERA PARTNERS","og_description":"TWYMEEG\u00ae is a first-in-class drug with a unique dual mechanism of action for the treatment of Type 2 Diabetes across the continuum of the current treatment paradigm, both as a monotherapy or as an add-on to other glucose lowering therapies. The approval in Japan triggers a JPY 1.75 billion (approximately EUR 13.3 million, USD 15.9...","og_url":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2021-06-23T14:23:51+00:00","article_modified_time":"2021-06-24T08:03:43+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Poxel announces the approval of Twymeeg","datePublished":"2021-06-23T14:23:51+00:00","dateModified":"2021-06-24T08:03:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/"},"wordCount":211,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/","url":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/","name":"Poxel announces the approval of Twymeeg - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2021-06-23T14:23:51+00:00","dateModified":"2021-06-24T08:03:43+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Poxel announces the approval of Twymeeg"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/7869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=7869"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/7869\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=7869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=7869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}